Tenaya Therapeutics $75 million stock and pre-funded warrants offering
The stock is listed on the Nasdaq Global Select Market
Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with a $75 million SEC-registered common stock and pre-funded warrants offering by Tenaya Therapeutics, Inc. Tenaya’s common stock is listed on the Nasdaq Global Select Market under the symbol “TNYA.”
Based in South San Francisco, California, Tenaya is a biotechnology company that discovers, develops and delivers curative therapies to address the underlying drivers of heart disease. Tenaya is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: gene therapy, cellular regeneration and precision medicine.
The Davis Polk corporate team included partner Alan F. Denenberg and associates Beth LeBow, Alex DeGroat and Henry Hawkins. Partner David R. Bauer and associates David A. Frey and Alexis N. Wallace provided intellectual property advice. The tax team included partner Mario J. Verdolini and associate Ted Lee. Members of the Davis Polk team are based in the Northern California and New York offices.